View More Recent Stories

May 26, 2020 07:45AM Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia
May 14, 2020 08:00AM Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131
May 7, 2020 08:15AM Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update
Mar 9, 2020 08:00AM Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update
Feb 19, 2020 08:06AM Cellectar Biosciences (CLRB) Reports CLR 131 Achieves Primary Efficacy Endpoints from Ph. 2 CLOVER-1 Study; Completes Ph. 1 R/R MM Dose Escalation Study
Feb 19, 2020 08:00AM Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Mu
Jan 9, 2020 08:00AM Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
Jan 7, 2020 08:14AM Cellectar Biosciences (CLRB) Appoints Dr. Igor Grachev as Chief Medical Officer
Jan 7, 2020 08:00AM Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer
Jan 6, 2020 08:23AM Cellectar Biosciences (CLRB) Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma
Jan 6, 2020 08:00AM Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)
Dec 19, 2019 08:00AM Cellectar Biosciences to Present at Biotech Showcase 2020
Dec 16, 2019 08:05AM Cellectar Biosciences (CLRB) Reports Data from 20 Patients Receiving Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
Dec 16, 2019 08:00AM Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
Dec 13, 2019 08:30AM Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium
Dec 9, 2019 08:33AM Cellectar Biosciences (CLRB) Announces Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at ASH
Dec 9, 2019 08:30AM Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference
Dec 2, 2019 08:30AM Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference
Nov 12, 2019 08:00AM Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
Oct 30, 2019 08:00AM Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oct 17, 2019 08:00AM Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
Oct 15, 2019 08:00AM Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
Nov 15, 2016 10:06AM Cellectar Biosciences (CLRB) Taps INC Research (INCR) to Oversee CLR Phase 2 in Multiple Myeloma, Select Hematologic Malignancies
Nov 15, 2016 10:00AM Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Addition
Jul 21, 2016 08:30AM StockNewsNow.com Publishes New SNNLive Video Interview with Cellectar Biosciences, Inc. Discussing Corporate Updates and Clinical Development
View More Recent Stories